Vanguard Group
VRPX

Vanguard Group’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Vanguard Group’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-265
Closed -$21.2K – 4516
2023
Q4 		$21.2K Buy
265
+4
+2% +$599 ﹤0.01% 4444
2023
Q3 		$52.1K Hold
261
– – ﹤0.01% 4408
2023
Q2 		$70.4K Hold
261
– – ﹤0.01% 4421
2023
Q1 		$51.1K Sell
261
-450
-63% -$100K ﹤0.01% 4465
2022
Q4 		$111K Sell
711
-773
-52% -$176K ﹤0.01% 4378
2022
Q3 		$441K Buy
1,484
+116
+8% +$41.8K ﹤0.01% 4246
2022
Q2 		$575K Hold
1,368
– – ﹤0.01% 4256
2022
Q1 		$759K Buy
1,368
+59
+5% +$34.4K ﹤0.01% 4292
2021
Q4 		$1.12M Buy
1,309
+193
+17% +$199K ﹤0.01% 4238
2021
Q3 		$1.34M Buy
+1,116
New +$2.34M ﹤0.01% 4178

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Vanguard Group's VRPX Position: Q1 2024 in Review

Vanguard Group sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 265 shares — an estimated $21.2K sold.

Vanguard Group first reported a position in VRPX in Q3 2021 and held it in 10 quarters. The position peaked at $1.34M in Q3 2021. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • Vanguard Group reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 265 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $21.2K.
  • Vanguard Group first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Vanguard Group's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $1.34M in Q3 2021.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.